Gilead Sciences, Inc. (GILD) earnings on August 4, 2026
More Gilead Sciences, Inc. earnings
Prior outlook: Pessimistic Outcome: Accurate
Gilead Sciences shares fell 1.9% after earnings, despite an intraday high of 3.1%, with analysts reiterating ratings and adjusting targets.
GILD price around the earnings
131.76
Change: -1.9%
2026-08-05, 20:00 UTC
Start of the measured window
End of the measured window
129.67
132.61
135.54
138.48
134.38
August 4, 2026
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
- Results released
Pre-release: Legal win supports company numbers, but trajectory collapsed sharply into earnings.
Context analyzed before publication
- Trend
- Stock experienced a sharp collapse in trajectory from positive to significantly negative into earnings.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.69
- Analysts covering the stock
- 27
- Average price target
- 157.15
- Lowest price target
- 120
- Highest price target
- 180
- Upside to price target
- 17.1%
- Quarterly earnings growth
- 53.7%
- Revenue growth
- 4.4%
- Forward EPS
- 9.62
- Trailing EPS
- 7.34
- Analyst moves in the last 60 days
- 9
- Strong buy: 6
- Buy: 16
- Hold: 7
- Sell: 0
- Strong sell: 0
- Strong buy
- 6
- Buy
- 16
- Hold
- 7
- Sell
- 0
- Strong sell
- 0
- July 29, 2026 · Barclays: Maintains rating (Equal-Weight → Equal-Weight)
- July 27, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- July 21, 2026 · Leerink Partners: Downgrades rating (Outperform → Market Perform)
- July 8, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- July 7, 2026 · RBC Capital: Maintains rating (Sector Perform → Sector Perform)
- July 7, 2026 · Truist Securities: Maintains rating (Buy → Buy)
- July 6, 2026 · Cantor Fitzgerald: Reiterates rating (Overweight → Overweight)
- July 6, 2026 · HSBC: Upgrades rating (Hold → Buy)
- June 16, 2026 · Cantor Fitzgerald: Reiterates rating (Overweight → Overweight)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (8)
- SpaceX Could Swing $204 Billion After Earnings (opens in a new tab) — Benzinga
- "California Supreme Court Rules In Favor Of Gilead Sciences In 'Duty To Innovate' Case Involving HIV Drugs" - Reuters (opens in a new tab) — Benzinga
- Eli Lilly Could Swing Over $76 Billion In Value After Earnings (opens in a new tab) — Benzinga
- Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145 (opens in a new tab) — Benzinga
- Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial (opens in a new tab) — Benzinga
- Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165 (opens in a new tab) — Benzinga
- Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer (opens in a new tab) — Benzinga
- Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 131.21
- Average true range (ATR)
- 2.5%
- Distance to 52-week high
- -12.8%
- 14-day change (14d)
- -1.5%
- 30-day change (32d)
- -0.0%
- 30-day relative strength
- +1.7%
- QQQ change (32d)
- -1.8%
- Nearest support
- 130.41
- Distance to nearest support
- 0.6%
- Nearest resistance
- 131.36
- Distance to nearest resistance
- 0.1%
- Volume accumulation ratio (14d / 46d)
- 0.8
- Mid: 130.41 (0.6% away, 0.24 ATR, 13 touches)
- Major: 129.23 (1.5% away, 0.6 ATR, 42 touches)
- Major: 127.96 (2.5% away, 0.98 ATR, 45 touches)
- Major: 131.36 (0.1% away, 0.04 ATR, 48 touches)
- Major: 132.79 (1.2% away, 0.47 ATR, 38 touches)
- Mid: 133.67 (1.9% away, 0.74 ATR, 16 touches)
Trends
Evidence
- Average earnings surprise
- +6.9%
- May 7, 2026: actual EPS 2.03 vs estimate 1.91 (surprise +6.2%)
- February 10, 2026: actual EPS 1.86 vs estimate 1.81 (surprise +2.8%)
- October 30, 2025: actual EPS 2.47 vs estimate 2.14 (surprise +15.7%)
- August 7, 2025: actual EPS 2.01 vs estimate 1.96 (surprise +2.7%)
Expected move
- Implied move
- +3.8%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 3.8%
- 75th percentile move
- 4.8%
- 90th percentile move
- 7.6%
- Up / down moves
- 10 / 10
- Average up move
- +5.5%
- Average down move
- -3.0%
Monitoring and close
What Gilead Sciences, Inc. reported
- Status
- Finished
| Actual EPS | -6.75 |
|---|---|
| EPS estimate | -7.25 |
| EPS surprise | +6.9% |
Gilead posted a Q2 loss on acquisition costs but beat revenue estimates on strong HIV drug sales. Adjusted annual guidance improved, while GAAP outlook was lowered.
Sources (13)
- Gilead's High-Profile HIV Drug Beat, But That's Not What Grabbed Attention (opens in a new tab) — Investor's Business Daily
- Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year (opens in a new tab) — Benzinga
- Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates (opens in a new tab) — Zacks
- AHF Crowns Gilead Corporate Welfare King (opens in a new tab) — Yahoo
- Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026 (opens in a new tab) — StockStory
- Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue (opens in a new tab) — The Wall Street Journal
- Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story (opens in a new tab) — Barrons.com
- Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up (opens in a new tab) — Investor's Business Daily
- Gilead second-quarter sales rise 8%, beating Wall Street estimates (opens in a new tab) — Reuters
- Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est (opens in a new tab) — Benzinga
- Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est (opens in a new tab) — Benzinga
- Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate (opens in a new tab) — Benzinga
- Earnings per share: $-6.75 vs $-7.25 expected — above expectations. — Yahoo Finance
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -1.9%
- Max favorable move (MFE)
- 3.6%
- Max adverse move (MAE)
- 3.1%